MX385451B - Proteínas sintéticas autoensamblables. - Google Patents

Proteínas sintéticas autoensamblables.

Info

Publication number
MX385451B
MX385451B MX2015012461A MX2015012461A MX385451B MX 385451 B MX385451 B MX 385451B MX 2015012461 A MX2015012461 A MX 2015012461A MX 2015012461 A MX2015012461 A MX 2015012461A MX 385451 B MX385451 B MX 385451B
Authority
MX
Mexico
Prior art keywords
self
present disclosure
immunogenic
limited
antigens
Prior art date
Application number
MX2015012461A
Other languages
English (en)
Other versions
MX2015012461A (es
Inventor
Daniel T Verhamme
Erik D´HONDT
Keith Alan Charlton
Original Assignee
Bioven 3 Ltd
Daniel T Verhamme
Erik D´Hondt
Keith Alan Charlton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioven 3 Ltd, Daniel T Verhamme, Erik D´Hondt, Keith Alan Charlton filed Critical Bioven 3 Ltd
Publication of MX2015012461A publication Critical patent/MX2015012461A/es
Publication of MX385451B publication Critical patent/MX385451B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una proteína sintética recombinante caracterizad porque comprende: una secuencia polipeptídica monomérica capaz de ensamblarse en homo-multímeros estables; en donde la secuencia polipeptídica monomérica incluye: una subunidad ß sintética de un grupo a1B5 de holotoxinas bacterianas derivadas de una subunidad ß de la toxina del Cólera (CTB), en donde la subunidad CTB incluye las mutaciones con cambio de sentido T1F, P2T, Q3D, N4I, M317I, A38I, I39L, I40V, T78S, E79N, A80S, A95S, A102V, y N103R, en donde las mutaciones con cambio de sentido son numeradas con relación a la SEQ ID NO: 1, un espaciador peptídico, y un polipéptido que incluye un factor de crecimiento o parte del mismo, seleccionado del grupo que consiste de IGF1, IGF-2, FGF1, FGF2, TGF-a TGF-B, VEFG-A, VEGF-B ,VEFG-C, VEGF-D, PDGF, NGF, EGF, HGF, BMPs, PDL1 y IL-1, IL-2, IL-3, IL-4, IL-5, y IL-6, en donde el polipéptido está separado de la subunidad B sintética mediante el espaciador peptídico.
MX2015012461A 2013-03-15 2014-03-17 Proteínas sintéticas autoensamblables. MX385451B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791268P 2013-03-15 2013-03-15
PCT/IB2014/001125 WO2014140894A2 (en) 2013-03-15 2014-03-17 Self-assembling synthetic proteins

Publications (2)

Publication Number Publication Date
MX2015012461A MX2015012461A (es) 2016-08-08
MX385451B true MX385451B (es) 2025-03-18

Family

ID=51225849

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012461A MX385451B (es) 2013-03-15 2014-03-17 Proteínas sintéticas autoensamblables.
MX2021010021A MX2021010021A (es) 2013-03-15 2015-09-11 Proteínas sintéticas autoensamblables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010021A MX2021010021A (es) 2013-03-15 2015-09-11 Proteínas sintéticas autoensamblables.

Country Status (14)

Country Link
US (3) US10736948B2 (es)
EP (1) EP2970409A2 (es)
JP (1) JP6873530B2 (es)
KR (2) KR102427429B1 (es)
CN (2) CN111978409B (es)
AU (1) AU2014229561B2 (es)
BR (1) BR112015023402A2 (es)
CA (1) CA2904506A1 (es)
HK (1) HK1214606A1 (es)
IL (3) IL286537B (es)
MX (2) MX385451B (es)
MY (1) MY187936A (es)
RU (1) RU2747857C2 (es)
WO (1) WO2014140894A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160333087A1 (en) 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
CN111246878A (zh) * 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
US20220273790A1 (en) * 2019-06-18 2022-09-01 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
AU2020301638A1 (en) * 2019-06-25 2022-02-17 In3Bio Ltd. Stabilized chimeric synthetic proteins and therapeutic uses thereof
CA3157334A1 (en) 2019-11-07 2021-05-14 Miguel Angel MOLINA-VILLA Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
CN114019166B (zh) * 2021-09-27 2024-02-27 浙江省食品药品检验研究院 一种检测龙葵素的试纸条及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
BR9712852A (pt) 1996-10-23 1999-11-16 Univ Pennsylvania Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
IL149009A0 (en) 1999-10-08 2002-11-10 Active Biotech Ab Ab5 toxin b subunt mutants with altered chemical conjugation characteristics
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP1452556B1 (en) 2001-06-21 2009-06-10 Teijin Limited Near infrared ray shielding film
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
WO2003052064A2 (en) 2001-12-14 2003-06-26 Centocor Inc. Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
US20060078552A1 (en) * 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型５量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CN1905892A (zh) * 2003-12-05 2007-01-31 西北大学 自组装的肽两亲物和用于生长因子传递的相关方法
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
US7946815B2 (en) 2007-03-27 2011-05-24 Siemens Energy, Inc. Airfoil for a gas turbine engine
JP2011501946A (ja) 2007-10-25 2011-01-20 ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド 変異体ＨｎＲＮＰＧの癌関連エピトープに対する抗体およびその使用法
EP2219669A4 (en) 2007-12-19 2011-03-09 Mivac Dev Aktiebolag COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES
EP2288380B1 (en) 2008-06-09 2020-06-03 Bharat Biotech International Limited Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
JP2010050586A (ja) 2008-08-20 2010-03-04 Nec Corp 通信装置及びそれに用いる装置コンポーネント複合冗長化方法
EP2363472B1 (en) * 2008-10-31 2014-12-10 Dnavec Corporation Method for enhancing expression of recombinant protein
EP3482769B1 (en) * 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
JP2011097930A (ja) * 2009-10-07 2011-05-19 Hokkaido Univ 光活性化生理機能センサータンパク質
RU2480524C2 (ru) * 2010-09-13 2013-04-27 Учреждение Российской академии наук Институт биоорганической химии им. академии М.М. Шемякина и Ю.А. Овчинникова РАН Конструкция на основе белковой пары барназа-барстар и способ ее получения
JP6101638B2 (ja) * 2011-03-03 2017-03-22 ザイムワークス，インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物
CN102604993B (zh) 2012-01-10 2013-03-20 天津耀宇生物技术有限公司 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法

Also Published As

Publication number Publication date
JP6873530B2 (ja) 2021-05-19
US20230042534A1 (en) 2023-02-09
IL241116A0 (en) 2015-11-30
CN111978409B (zh) 2024-01-26
CN111978409A (zh) 2020-11-24
EP2970409A2 (en) 2016-01-20
KR102391734B1 (ko) 2022-04-29
MX2021010021A (es) 2021-12-10
HK1214606A1 (zh) 2016-07-29
IL286537A (en) 2021-10-31
BR112015023402A2 (pt) 2017-08-22
AU2014229561B2 (en) 2018-06-07
AU2014229561A1 (en) 2015-10-29
IL286537B (en) 2022-07-01
MX2015012461A (es) 2016-08-08
KR20210005294A (ko) 2021-01-13
CA2904506A1 (en) 2014-09-18
US10736948B2 (en) 2020-08-11
US11419923B2 (en) 2022-08-23
US20160095910A1 (en) 2016-04-07
RU2747857C2 (ru) 2021-05-17
WO2014140894A3 (en) 2015-02-19
MY187936A (en) 2021-10-29
US12433939B2 (en) 2025-10-07
JP2016517402A (ja) 2016-06-16
US20200297827A1 (en) 2020-09-24
IL273051A (en) 2020-04-30
IL241116B (en) 2020-03-31
WO2014140894A2 (en) 2014-09-18
KR20150139513A (ko) 2015-12-11
IL273051B (en) 2021-10-31
CN105209481B (zh) 2020-08-25
CN105209481A (zh) 2015-12-30
RU2015143217A (ru) 2017-04-27
RU2019109120A (ru) 2019-06-13
KR102427429B1 (ko) 2022-08-01

Similar Documents

Publication Publication Date Title
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
CY1121934T1 (el) Αντισωματα anti-fcrn
MX2021010021A (es) Proteínas sintéticas autoensamblables.
CR20150258A (es) Anticuerpos anti-ceacam5 y usos de éstos
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
MX2018005047A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano.
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
PH12015500480A1 (en) Antibody formulations and uses thereof
MX2019007921A (es) Nuevos agentes de union a ha.
EA201790239A1 (ru) Молекула-носитель для антигенов
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
EA201590187A1 (ru) Моноклональные антитела для применения в диагностике и терапии злокачественных опухолей и аутоиммунного заболевания
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
EA201591796A1 (ru) Антитела к cd52
BR112015023738B8 (pt) Vacinas de nucleoproteina influenza
MX2016004754A (es) Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados.
MX2015011257A (es) Peptido novedoso que tiene 5 epitopos de linfocitos t citotoxicos enlazados.
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.